Biognosys

At Biognosys, we believe that we can dramatically improve human health by deciphering the biological complexity of diseases. By providing access to the proteome on all levels, we enable life science researchers and drug hunters to unlock true discoveries. We push the boundaries of what is possible with our proteomics solutions to help usher in a new age of bioengineering and precision medicine. When we look at the proteome differently, we envision a better world! To learn more about our vision, mission, and values, watch our new corporate video and visit: http://ow.ly/nlPM50KNHhT #Proteomics #MassSpectrometry #DrugDiscovery #DrugDevelopment #PrecisionMedicine

🌟 We are happy to share the latest pre-print from the Yansheng Liu lab! 🌟 📰 In this study, researchers introduce a new workflow to probe drug-resistant cancer cells that integrates machine learning and pulsed-SILAC DIA. 💻The workflow features the unique machine learning capabilities of Spectronaut 19 to extract the most IDs for both labeled and unlabeled peptides. 📊This work reveals significant insights into cisplatin resistance in an aneuploid cancer cell model, highlighting correlations between transcript regulation and protein degradation. 👉 Read the full pre-print here: https://lnkd.in/dmxs3Z3u #TeamMassSpec #Spectronaut19 #Proteomics

At #HUPO2024, we presented a poster highlighting a collaboration with The Johns Hopkins University where we shared innovative research using our TrueDiscovery® platform, profiling paired CSF and plasma samples in a comprehensive #proteomics study. Key Highlights: 🧬5,599 proteins were quantified in #CSF and 3,112 proteins in #plasma, revealing key aging-related changes. 🧪Upregulation in extracellular matrix, coagulation, and inflammatory pathways in CSF, and downregulation of IGF-1 signaling in plasma. 🧠We uncovered differential cleavage, alternative splicing, and phosphorylation in genes linked to #neurodegeneration. The findings spotlight new #biomarkers and potential therapeutic targets for brain aging and neurodegeneration. 📥 Download the poster here: https://lnkd.in/dp6wDbk8 #Aging #MassSpectrometry #DrugDiscovery

Attending the 8th Dermatology Drug Development Summit in Boston, MA? Make sure to join us at our booth!👋 Meet Lida Vadakumchery, PhD to discuss how our #proteomics solutions can bring your #DrugDevelopment research to the next level. 🔝🔬

Our #DigitalProteome™ platform was showcased on a poster at #HUPO2024 and is now available for download. 🌟 This qualitative and quantitative proteome library offers unparalleled insights into tissue biology, enabling the exploration of diverse proteoforms across various tissue types, such as protein isoforms and non-canonical translation products. 📊 Highlights include: ➡️ Extensive quantitative proteome map across 22 human tissues, 23 mouse tissues, and 24 rat tissues. ➡️ In-depth tissue-specific protein expression levels, with proof-of-concept examples on CDK proteins and E3 ligases. ➡️ Supports in silico pharmacological assessments, revealing potential drug targets and off-targets. 📥 Download the poster and see how DigitalProteome™ can accelerate your clinical & pre-clinical research: https://lnkd.in/djX8a6fF #Proteomics #BiomarkerDiscovery #DrugDevelopment

Check out our latest technical note on DIA for biomarker discovery! 🔎 We benchmarked Spectronaut 19 against another popular DIA #proteomics search software using ground-truth controlled quantitative experiments (CQE) acquired on the timsTOF MS platform. 👉 Download to learn how #Spectronaut 19 continues to provide gold-standard performance for reliable #biomarker identification and quantification: https://lnkd.in/d_urE7Ge

We are starting Day Two of Oxford Global Discovery US! Come visit Valesca Anschau Ph.D., Eric Miele and Lida Vadakumchery, PhD at booth #14. 👋 And, don't miss the talk by our Associate Scientific Director Valesca Anschau today, November 8, at 11:45 AM, titled ''Unlocking Discoveries from Plasma: Bridging depth, throughput and sensitivity''. 🔬 See you there! #Proteomics #MassSpectrometry #DrugDiscovery

New White Paper Alert! 📢 We're happy to unveil our latest white paper showcasing our comprehensive plasma proteomics services powered by the #TrueDiscovery® P2 Enrichment System—a cutting-edge solution for high-throughput plasma #proteomics! 🩸 Highlights: ✨ Comprehensive plasma workflows with licensing options ✨ Flexible, high-throughput (DeepHT) & UltraDeep workflows ✨ Complimentary with Alamar Biosciences, Inc. #NULISA™ assays ✨ Oncology case study demonstrating clinical potential in cancer research Explore how the P2 Enrichment System is redefining biomarker detection from #plasma & unlocking valuable insights for oncology and beyond. 🔗 Available now for download on our website: https://lnkd.in/dteVZKcd #MassSpectrometry #BiomarkerDiscovery #ClinicalResearch

Join us at Oxford Global Discovery US in Boston on November 7-8!🔬 On Friday, November 8 at 11:45 AM, our Associate Scientific Director Valesca Anschau Ph.D. will present on how our TrueDiscovery® platform is transforming #DrugDiscovery and #ClinicalResearch. Also, don't miss the chance to connect with our team during exhibition hours—we'd love to share our insights and hear your thoughts!👋 #Proteomics #MassSpectrometry

Thank you to everyone who joined us for our Lunch & Learn at Campus Berlin-Buch GmbH yesterday! 🤩 We had a full room of #proteomics enthusiasts who learned from our team about the latest in using next-gen proteomics services for drug development and clinical research. 🧬💡 ✉️ Want to be informed of future events in your area? Sign up for our newsletter here: https://lnkd.in/dwXFw9tS #MassSpectrometry #DrugDiscovery #ClinicalResearch